GlobalData on MSN7d
Palatin concludes Phase II trial of combination therapy for obesity
Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...
News Medical on MSN9d
High discontinuation rates of GLP-1 agonists found among patients with obesity
Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Yahoo Finance7d
Palatin concludes Phase II trial of combination therapy for obesity
a glucagon-like peptide-1 (GLP-1)/gastric inhibitory polypeptide (GIP), to treat obesity. The final output collection and quality control will be completed soon, with top-line data anticipated ...